Eisai Inc. -
Eisai Inc. (pronounced ā-zī) is a U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd, a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business.
Headquartered in Woodcliff Lake, New Jersey, we are dedicated to a tradition of genuine concern for people and are driven by the desire to help meet the diverse health care needs of patients and their families and caregivers. We are an agile, entrepreneurial organization managed by experienced leadership, backed by the strength, stability and historical successes of Eisai Co., Ltd., which has a strong and lasting commitment to the U.S. market.
Our heritage and mission have earned us recognition as an innovative, efficient, solution-oriented pharmaceutical company - a company that effectively works with healthcare professionals, hospitals and managed care organizations to develop and market specialty products that help address unmet needs. Our ability to forge strong alliances gives us a competitive edge.
In the United States, our rapid growth and strong performance result from putting patients and their families first when making decisions and from empowering the people who manage our operations. Eisai employees personify our values of integrity, respect, professionalism, quality and teamwork.
As you continue exploring our corporate web site, you will learn more about how our commitment to hhc is a motivating force for everything we do and everything we produce.
Eisai Center for Genetics Guided Dementia Discovery (G2D2) -
The Eisai Center for Genetics Guided Dementia Discovery (G2D2) is an industry-unique drug discovery biotech with a diverse group of passionate, dedicated and collaborative scientists committed to helping eradicate Alzheimer’s disease and other dementias. Recognizing the potential for human genetics, data sciences and precision chemistry to disrupt the drug discovery paradigm, Eisai established G2D2 to accelerate the discovery of innovative therapeutics. G2D2 is committed to accelerating drug discovery premised upon robust insights from human biology, and driving multi-disciplinary team-based progress towards addressing real unmet patient needs.
At G2D2, we focus not only on how such data help identify and validate therapeutic targets, but also to guide novel approaches to drug such targets and match them to the right patient at the right time. Our precision chemistry strategy - in the context of insights from human genetics - is uniquely positioned to deliver tailor-designed small molecule, anti-sense oligo-nucleotide, and other solutions for targeted therapeutics.
Our new cutting-edge 50,000-square-foot facility is strategically located in Cambridge, MA, to accelerate collaborations with leading research institutes in this world-class biotech hub. Our facility has been designed around a novel open-lab concept, enabling chemists, biologists, automation and other scientists to work together in a single common and integrated lab space. Our labs include state-of-the-art capabilities in medicinal and process chemistry, in-vitro and in-vivo biology, microscopy, chemical and structural biology, automation and screening, and several other discovery technologies and platforms.
You will join a highly interactive and collaborative team spanning a broad range of drug discovery capabilities. We highly value both internal and external collaborations, and you will become involved in flexible research models with a range of external scientific partners to accelerate delivery of innovative medicines. As an Eisai employee you will spend at least 1% of your working time with patients and families to ensure that the innovation you drive is based on an understanding of their real needs.
More information about G2D2 is provided here (http://eisai.mediaroom.com/2018-06-12-Eisai-Inc-to-Launch-Center-for-Genetics-Guided-Dementia-Discovery-in-Cambridge-Massachusetts) and here (https://us.eisai.com/research/g2d2), and about Eisai's Neurology strategy and pipeline are provided here (https://www.eisai.com/index.html).